XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2016 Cowen and Company 36th Annual Health Care Conference. The live presentation will occur at 5:40 a.m. Pacific Time (8:40 a.m. Eastern Time) on Wednesday, March 9, 2016. A replay of the presentation will also be available. To access the live presentation via the Web, please go to www.XenoPort.com. Please connect to the Web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast. A replay of the Webcast can be accessed for a minimum of one month and will be available approximately 24 hours after the live presentation. About XenoPort XenoPort, Inc. is a biopharmaceutical company focused on commercializing HORIZANT ® (gabapentin enacarbil) Extended-Release Tablets in the United States. XenoPort has entered into a clinical trial agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under which the NIAAA has initiated a clinical trial evaluating gabapentin enacarbil as a potential treatment for patients with alcohol use disorder. REGNITE ® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort has granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Indivior UK Ltd. for all indications. XenoPort's other product candidates include XP23829, a novel fumaric acid ester prodrug that is a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis or patients with relapsing forms of multiple sclerosis, and XP21279, a prodrug of levodopa that is a potential treatment for patients with idiopathic Parkinson's disease. To learn more about XenoPort, please visit the website at www.XenoPort.com. HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.